EXCELLENT POST CARTER!! A SUPERB REVIEW OF THE BIOTECH SECTOR!!!
Very clearly you've done your homework.
I hope everyone here is paying attention to your post for reason it spells out what can and does happen in the Biotech sector especially related to largely "unknown" Biopharmas with no earnings and heavily in debt, BUT with a drug patent pipeline worth Billions.
RGBP has at least 20 with (1) FDA Approved Patent for (2) INDs for entering clinical trials to treat pancreatic and colon cancer...and to boot they have partnership licensing arrangements with Oncology Pharma to take that patent into clinical trials authorized by the FDA. That's an epic "game changer" for RGBP! This totally changed its perceived Market Value overnight to ALL the Big Pharmas out there.
That Patent has at least a 95% chance of passing through all 4 Clinical Trial phases and making it to Market. It is a Multi-Billion Dollar Patent with mRNA disruptive biotechnology which like Kite Pharma, makes them a prime target for Buy Out by a Big Pharma. The chances of that happening are very high...more likely than not!
Lastly, I find it very interesting and coincidental that Kite Pharma, just before they were bought out by Gilead for $12 Billion, were a developmental stage Biopharma engaged in discovery of immune based therapies to treat various cancers 100% identical to RGBP! And not only this, like RGBP, they were based in Los Angeles, California.
History repeats itself....
Be well and prosper
AI
Market Data 
Markets 
